CORMEDIX INC
CRMDNASDAQUS Equity
$208.01▲ $9.98 (+4.80%)
Simulated price1h—
24h▲ 4.8%
7d▲ 2705.3%
14d▲ 2791.0%
30d▲ 2401.6%
1y▲ 1713.5%
🏦Market Cap
$302.41B
Large Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
62
Fair
Trading Snapshot
- Day Range
- $205.42 – $212.04
- 52-Week Range
- —
- Volume
- $3.63B
- Avg Volume
- $4.54B
- Shares Outstanding
- —
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $27.49B
- Last Q Revenue
- $6.63B
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own CRMD
- ✓High-growth profile — revenue up +40.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 71% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$27.49B▲ +47.5% YoY
Gross Margin (TTM)
70.5%▲ +2.4% YoY
Operating Income (TTM)
$6.96B▲ +47.5% YoY
Free Cash Flow (TTM)
$8.22B▲ +47.5% YoY
About CORMEDIX INC
A company profile for CORMEDIX INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
62/100
Analyst Price Target
ⓘAverage Target
$226.20
▲ +8.7% Upside
High Target$265.23
Low Target$209.35
Based on 37 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
CORMEDIX INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift CRMD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Reuters·1d ago
CORMEDIX INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.